Replimune Group Inc.

12.84
-0.28 (-2.13%)
At close: Feb 11, 2025, 3:59 PM
12.85
0.08%
After-hours Feb 11, 2025, 04:09 PM EST
undefined%
Bid 12.26
Market Cap 967.37M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.04
PE Ratio (ttm) -4.22
Forward PE n/a
Analyst Buy
Ask 14.16
Volume 274,675
Avg. Volume (20D) 925,171
Open 13.03
Previous Close 13.12
Day's Range 12.56 - 13.03
52-Week Range 4.92 - 17.00
Beta undefined

About REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2018
Employees 331
Stock Exchange NASDAQ
Ticker Symbol REPL

Analyst Forecast

According to 6 analyst ratings, the average rating for REPL stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 32.40% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 weeks ago
+9.87%
Replimune Group shares are trading higher after HC... Unlock content with Pro Subscription
3 weeks ago
+16.86%
Replimune Group shares are trading higher after the company announced the FDA has accepted the biologics license application for RP1 in combination with nivolumab for patients with advanced melanoma